BACKGROUND: Aberrations of the p53 tumor suppressor gene are common events in squamous cell carcinomas of the head and neck (SCCHN). However, reported frequencies range considerably, and the predictive value of aberrant p53 is continuing to be an issue of controversy. These inconsistencies are possibly caused by methodical limitations. METHODS: In cell lines established from 23 SCCHN, we performed sequence analysis of p53 mRNA and genomic DNA, as well as protein detection using immunohistochemistry and Western blotting. RESULTS: Of the 23 SCCHN, 21 (91%) tumors have aberrant or no p53, including four aberrations (19%) located outside the usually examined exons 5 to 9. A second allele is present in 11, and the respective transcript in 4 tumors. Expression of protein could be detected in only 12 of the 21 p53 aberrant tumors (57%). CONCLUSIONS: Depending on the methodical approach applied, a considerable number of SCCHN may be misclassified regarding their p53 status. Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 868-873, 2002
BACKGROUND: Aberrations of the p53 tumor suppressor gene are common events in squamous cell carcinomas of the head and neck (SCCHN). However, reported frequencies range considerably, and the predictive value of aberrant p53 is continuing to be an issue of controversy. These inconsistencies are possibly caused by methodical limitations. METHODS: In cell lines established from 23 SCCHN, we performed sequence analysis of p53 mRNA and genomic DNA, as well as protein detection using immunohistochemistry and Western blotting. RESULTS: Of the 23 SCCHN, 21 (91%) tumors have aberrant or no p53, including four aberrations (19%) located outside the usually examined exons 5 to 9. A second allele is present in 11, and the respective transcript in 4 tumors. Expression of protein could be detected in only 12 of the 21 p53 aberrant tumors (57%). CONCLUSIONS: Depending on the methodical approach applied, a considerable number of SCCHN may be misclassified regarding their p53 status. Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 868-873, 2002
Authors: Russell Moser; Chang Xu; Michael Kao; James Annis; Luisa Angelica Lerma; Christopher M Schaupp; Kay E Gurley; In Sock Jang; Asel Biktasova; Wendell G Yarbrough; Adam A Margolin; Carla Grandori; Christopher J Kemp; Eduardo Méndez Journal: Clin Cancer Res Date: 2014-08-15 Impact factor: 12.531
Authors: Katerina I Leonova; Leonid Brodsky; Brittany Lipchick; Mahadeb Pal; Liliya Novototskaya; Alex A Chenchik; Ganes C Sen; Elena A Komarova; Andrei V Gudkov Journal: Proc Natl Acad Sci U S A Date: 2012-12-10 Impact factor: 11.205
Authors: Mysore S Veena; Reason Wilken; Jun-Ying Zheng; Ankur Gholkar; Natarajan Venkatesan; Darshni Vira; Sameer Ahmed; Saroj K Basak; Clifton L Dalgard; Sandhiya Ravichandran; Raj K Batra; Noriyuki Kasahara; David Elashoff; Michael C Fishbein; Julian P Whitelegge; Jorge Z Torres; Marilene B Wang; Eri S Srivatsan Journal: J Biol Chem Date: 2014-10-20 Impact factor: 5.157
Authors: J P Klussmann; S Dinh; O Guntinas-Lichius; C Wittekindt; S Weissenborn; U Wieland; H P Dienes; T Hoffmann; E Smith; L Turek; E J M Speel; H J Pfister Journal: HNO Date: 2004-03 Impact factor: 1.284
Authors: C Gianna Hoffman-Luca; Daniel Ziazadeh; Donna McEachern; Yujun Zhao; Wei Sun; Laurent Debussche; Shaomeng Wang Journal: Clin Cancer Res Date: 2015-03-09 Impact factor: 12.531
Authors: Bernard Leroy; Luc Girard; Antoinette Hollestelle; John D Minna; Adi F Gazdar; Thierry Soussi Journal: Hum Mutat Date: 2014-05-06 Impact factor: 4.878
Authors: S F Preuss; A Weinell; M Molitor; M Stenner; R Semrau; U Drebber; S J Weissenborn; E J M Speel; C Wittekindt; O Guntinas-Lichius; T K Hoffmann; G D Eslick; J P Klussmann Journal: Br J Cancer Date: 2008-01-22 Impact factor: 7.640
Authors: Liam Masterson; David M Winder; Siolian L R Ball; Katie Vaughan; Martin Lehmann; Lars-Uwe Scholtz; Jane C Sterling; Holger H Sudhoff; Peter K C Goon Journal: BMC Cancer Date: 2016-06-13 Impact factor: 4.430